

Volker Auwärter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3297372/publications.pdf>

Version: 2024-02-01

175
papers

7,398
citations

50276

46
h-index

69250

77
g-index

182
all docs

182
docs citations

182
times ranked

3980
citing authors

#	ARTICLE	IF	CITATIONS
1	Separating the wheat from the chaff: Observations on the analysis of lysergamides LSD, MIPLA, and LAMPA. <i>Drug Testing and Analysis</i> , 2022, 14, 545-556.	2.6	8
2	Dental Plaque Concentrations of Methadone, Morphine and Their Metabolites in Opioid Replacement Therapy and in Postmortem Cases. <i>Journal of Analytical Toxicology</i> , 2022, 46, 633-640.	2.8	1
3	Qualitative and Quantitative Analysis of Tryptamines in the Poison of <i>Incilius alvarius</i> (Amphibia: Bufonidae). <i>Journal of Analytical Toxicology</i> , 2022, 46, 540-548.	2.8	4
4	Structure-activity relationships of valine, <i>tert</i> -leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. <i>RSC Medicinal Chemistry</i> , 2022, 13, 156-174.	3.9	11
5	Development and validation of a rapid LC-MS/MS method for the detection of 182 novel psychoactive substances in whole blood. <i>Drug Testing and Analysis</i> , 2022, 14, 202-223.	2.6	19
6	Investigation of the μ - and κ -opioid receptor activation by eight new synthetic opioids using the [³⁵ S]-GTP γ S assay: U μ -47700, isopropyl U μ -47700, U μ -49900, U μ -47931E, <i>N</i> -methyl U μ -47931E, U μ -51754, U μ -48520, and U μ -48800. <i>Drug Testing and Analysis</i> , 2022, 14, 1187-1199.	2.6	15
7	Structure elucidation of the novel synthetic cannabinoid Cumyl μ -Tosyl μ -Indazole μ -3 μ -Carboxamide (Cumyl μ -sINACA) found in illicit products in Germany. <i>Drug Testing and Analysis</i> , 2022, , .	2.6	6
8	The ADEBAR project – European and international provision of analytical data from structure elucidation and analytical characterization of NPS. <i>Drug Testing and Analysis</i> , 2022, , .	2.6	6
9	Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P μ -CAL μ -LAD. <i>Drug Testing and Analysis</i> , 2022, 14, 1503-1518.	2.6	7
10	The Novel Psychoactive Substance Cumyl-CH-MEGACLONE: Human Phase-I Metabolism, Basic Pharmacological Characterization and Comparison to Other Synthetic Cannabinoid Receptor Agonists with a β -Carboline-1-One Core. <i>Journal of Analytical Toxicology</i> , 2021, 45, 277-290.	2.8	15
11	Cumyl μ -CBMICA: A new synthetic cannabinoid receptor agonist containing a cyclobutyl methyl side chain. <i>Drug Testing and Analysis</i> , 2021, 13, 208-216.	2.6	21
12	Substances detected in used syringes of injecting drug users across 7 cities in Europe in 2017 and 2018: The European Syringe Collection and Analysis Project Enterprise (ESCAPE). <i>International Journal of Drug Policy</i> , 2021, 95, 103130.	3.3	17
13	Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB μ -4 μ -PICA, MDMB μ -4 μ -PINACA, ADB μ -4 μ -PINACA, and MMB μ -4CN μ -BUTINACA using a combination of binding and different CB ₁ receptor activation assays – Part II: Structure activity relationship assessment via a β -Arrestin recruitment assay. <i>Drug Testing and Analysis</i> , 2021, 13, 1402-1411.	2.6	18
14	Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB μ -4 μ -PICA, MDMB μ -4 μ -PINACA, ADB μ -4 μ -PINACA, and MMB μ -4CN μ -BUTINACA using a combination of binding and different CB ₁ receptor activation assays: Part I – Synthesis, analytical characterization, and binding affinity for human CB ₁ receptors. <i>Drug Testing and Analysis</i> , 2021, 13, 1383-1401.	2.6	19
15	New synthetic cannabinoids carrying a cyclobutyl methyl side chain: Human Phase I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl μ -CBMICA and Cumyl μ -CBMINACA. <i>Drug Testing and Analysis</i> , 2021, 13, 1499-1515.	2.6	15
16	Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB μ -4 μ -PICA, MDMB μ -4 μ -PINACA, ADB μ -4 μ -PINACA, and MMB μ -4CN μ -BUTINACA using a combination of binding and different CB ₁ receptor activation assays. Part III: The G protein pathway and critical comparison of different assays. <i>Drug Testing and Analysis</i> , 2021, 13, 1412-1429.	2.6	14
17	Pharmacological and metabolic characterization of the novel synthetic opioid bromphine and its detection in routine casework. <i>Forensic Science International</i> , 2021, 327, 110989.	2.2	9
18	A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: Comparing prison and general populations. <i>Drug Testing and Analysis</i> , 2021, 13, 841-852.	2.6	28

#	ARTICLE	IF	CITATIONS
19	NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity?. ACS Chemical Neuroscience, 2021, 12, 4020-4036.	3.5	7
20	Comprehensive structural characterisation of the newly emerged synthetic cannabimimetics Cumyl-BC[2.2.1]HpMeGaClone, Cumyl-BC[2.2.1]HpMINACA, and Cumyl-BC[2.2.1]HpMICA featuring a norbornyl methyl side chain. Forensic Chemistry, 2021, 26, 100371.	2.8	12
21	Dataset allowing for the identification of three new synthetic cannabimimetics featuring a norbornyl methyl side chain by spectrometric and spectroscopic techniques. Data in Brief, 2021, 39, 107628.	1.0	2
22	Detection of Nutmeg Abuse by Gas Chromatography–Mass Spectrometric Screening of Urine. Journal of Analytical Toxicology, 2020, 44, 103-108.	2.8	1
23	Quantification of Herbal Mixtures Containing Cumyl-PEGACLONE—Is Inhomogeneity Still an Issue?. Journal of Analytical Toxicology, 2020, 44, 81-85.	2.8	7
24	Metabolism of the benzodiazepines norflurazepam, flurazepam, fludiazepam and cinolazepam by human hepatocytes using high-resolution mass spectrometry and distinguishing their intake in authentic urine samples. Forensic Toxicology, 2020, 38, 79-94.	2.4	6
25	Detection and phase I metabolism of the 7-azaindole-derived synthetic cannabinoid 5F-ACB-7AICA including a preliminary pharmacokinetic evaluation. Drug Testing and Analysis, 2020, 12, 78-91.	2.6	21
26	Four cases of death involving the novel synthetic cannabinoid 5F-Cumyl-PEGACLONE. Forensic Toxicology, 2020, 38, 314-326.	2.4	21
27	Acute severe intoxication with cyclopropylfentanyl, a novel synthetic opioid. Toxicology Letters, 2020, 320, 109-112.	0.8	21
28	Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration. Drug Testing and Analysis, 2020, 12, 1144-1153.	2.6	12
29	A Recent Human Immunodeficiency Virus Outbreak Among People Who Inject Drugs in Munich, Germany, Is Associated With Consumption of Synthetic Cathinones. Open Forum Infectious Diseases, 2020, 7, ofaa192.	0.9	4
30	Post-Mortem Toxicology: A Systematic Review of Death Cases Involving Synthetic Cannabinoid Receptor Agonists. Frontiers in Psychiatry, 2020, 11, 464.	2.6	77
31	Application of a chiral high-performance liquid chromatography–tandem mass spectrometry method for the determination of 13 related amphetamine-type stimulants to forensic samples: Interpretative hypotheses. Drug Testing and Analysis, 2020, 12, 1354-1365.	2.6	10
32	Impact of legislation on NPS markets in Germany – The rise and fall of 5F-ADB. Drug Testing and Analysis, 2020, 12, 853-856.	2.6	21
33	Extraordinary long detection window of a synthetic cannabinoid metabolite in human urine – Potential impact on therapeutic decisions. Drug Testing and Analysis, 2020, 12, 391-396.	2.6	10
34	Detection of the recently emerged synthetic cannabinoid 4f-MDMB-BINACA in – legal high – products and human urine specimens. Drug Testing and Analysis, 2019, 11, 1377-1386.	2.6	44
35	Validation of an LC-MS/MS method for the quantitative analysis of 1P-LSD and its tentative metabolite LSD in fortified urine and serum samples including stability tests for 1P-LSD under different storage conditions. Journal of Pharmaceutical and Biomedical Analysis, 2019, 174, 270-276.	2.8	20
36	Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L-valine or L-tert-leucine. Drug Testing and Analysis, 2019, 11, 1183-1191.	2.6	37

#	ARTICLE	IF	CITATIONS
37	Postmortem concentrations of the synthetic opioid U-47700 in 26 fatalities associated with the drug. <i>Forensic Science International</i> , 2019, 301, e20-e28.	2.2	35
38	Metabolic Pathways and Potencies of New Fentanyl Analogs. <i>Frontiers in Pharmacology</i> , 2019, 10, 238.	3.5	94
39	Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3- <i>fluorophenmetrazine</i> (3-FPM). <i>Drug Testing and Analysis</i> , 2019, 11, 1009-1017.	2.6	5
40	Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro-4864). <i>Drug Testing and Analysis</i> , 2019, 11, 541-549.	2.6	16
41	Phase I metabolic profiling of the synthetic cannabinoids THJ-018 and THJ-2201 in human urine in comparison to human liver microsome and cytochrome P450 isoenzyme incubation. <i>International Journal of Legal Medicine</i> , 2019, 133, 1049-1064.	2.2	8
42	Cumyl-PEGACLONE: A comparatively safe new synthetic cannabinoid receptor agonist entering the NPS market?. <i>Drug Testing and Analysis</i> , 2019, 11, 347-349.	2.6	16
43	Structure-metabolism relationships of valine and tert-leucine-derived synthetic cannabinoid receptor agonists: a systematic comparison of the in vitro phase I metabolism using pooled human liver microsomes and high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2019, 37, 316-329.	2.4	24
44	5F-Cumyl-PINACA in <i>e-liquids</i> ™ for electronic cigarettes: comprehensive characterization of a new type of synthetic cannabinoid in a trendy product including investigations on the in vitro and in vivo phase I metabolism of 5F-Cumyl-PINACA and its non-fluorinated analog Cumyl-PINACA. <i>Forensic Toxicology</i> , 2019, 37, 186-196.	2.4	28
45	Human phase I metabolism of the novel synthetic cannabinoid 5F-CUMYL-PEGACLONE. <i>Forensic Toxicology</i> , 2019, 37, 154-163.	2.4	17
46	Mixed intoxication by the synthetic opioid U-47700 and the benzodiazepine flubromazepam with lethal outcome: Pharmacokinetic data. <i>Drug Testing and Analysis</i> , 2018, 10, 1336-1341.	2.6	37
47	Separation of positional isomers of nine 2-phenethylamine-derived designer drugs by liquid chromatography-tandem mass spectrometry. <i>Drug Testing and Analysis</i> , 2018, 10, 1184-1191.	2.6	8
48	Synthetic cannabinoids in hair – Pragmatic approach for method updates, compound prevalences and concentration ranges in authentic hair samples. <i>Analytica Chimica Acta</i> , 2018, 1006, 61-73.	5.4	30
49	Phase I metabolism of the recently emerged synthetic cannabinoid CUMYL-PEGACLONE and detection in human urine samples. <i>Drug Testing and Analysis</i> , 2018, 10, 886-891.	2.6	28
50	Phase I metabolism of the carbazole-derived synthetic cannabinoids EC-018, EC-2201, and MDMB-CHMCZCA and detection in human urine samples. <i>Drug Testing and Analysis</i> , 2018, 10, 1417-1429.	2.6	15
51	Activity-Based Detection of Cannabinoids in Serum and Plasma Samples. <i>Clinical Chemistry</i> , 2018, 64, 918-926.	3.2	44
52	Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in <i>legal high</i> ™ products and human urine samples. <i>Drug Testing and Analysis</i> , 2018, 10, 196-205.	2.6	78
53	Flubromazolam – Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. <i>Drug Testing and Analysis</i> , 2018, 10, 206-211.	2.6	49
54	Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYL-PEGACLONE. <i>Drug Testing and Analysis</i> , 2018, 10, 597-603.	2.6	37

#	ARTICLE	IF	CITATIONS
55	Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA. <i>Clinical Toxicology</i> , 2018, 56, 404-411.	1.9	46
56	Full validation of a method for the determination of drugs of abuse in non-mineralized dental biofilm using liquid chromatography-tandem mass spectrometry and application to postmortem samples. <i>Talanta</i> , 2018, 176, 360-366.	5.5	9
57	Designer Benzodiazepines: Another Class of New Psychoactive Substances. <i>Handbook of Experimental Pharmacology</i> , 2018, 252, 383-410.	1.8	56
58	Multivariate optimization of a method for the determination of fatty acids in dental biofilm by GC-MS. <i>Bioanalysis</i> , 2018, 10, 1319-1333.	1.5	5
59	Metabolism of Nine Synthetic Cannabinoid Receptor Agonists Encountered in Clinical Casework: Major in vivo Phase I Metabolites of AM-694, AM-2201, JWH-007, JWH-019, JWH-203, JWH-307, MAM-2201, UR-144 and XLR-11 in Human Urine Using LC-MS/MS. <i>Current Pharmaceutical Biotechnology</i> , 2018, 19, 144-162.	1.6	14
60	Pharmakologie und Toxikologie synthetischer Cannabinoidrezeptor-Agonisten. , 2018, , 389-409.		1
61	<i>In vitro</i> metabolism of the synthetic cannabinoid 3,5-AB-CHMFUPPYCA and its 5,3-regioisomer and investigation of their thermal stability. <i>Drug Testing and Analysis</i> , 2017, 9, 311-316.	2.6	19
62	Immunoassay screening in urine for synthetic cannabinoids – an evaluation of the diagnostic efficiency. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1375-1384.	2.3	46
63	Bad trip due to 25I-NBOMe: a case report from the EU project SPICE II plus. <i>Clinical Toxicology</i> , 2017, 55, 922-924.	1.9	13
64	Betel Nut Chewing in Iron Age Vietnam? Detection of Areca catechu Alkaloids in Dental Enamel. <i>Journal of Psychoactive Drugs</i> , 2017, 49, 11-17.	1.7	17
65	Evaluation of KIMS immunoassays on a cobas c 501 analyzer for drugs of abuse and ethyl glucuronide testing in urine for forensic abstinence control. <i>Drug Testing and Analysis</i> , 2017, 9, 1217-1223.	2.6	6
66	Activity-Based Detection of Consumption of Synthetic Cannabinoids in Authentic Urine Samples Using a Stable Cannabinoid Reporter System. <i>Analytical Chemistry</i> , 2017, 89, 9527-9536.	6.5	81
67	Three fatalities associated with the synthetic cannabinoids 5F-ADB, 5F-PB-22, and AB-CHMINACA. <i>Forensic Science International</i> , 2017, 281, e9-e15.	2.2	74
68	Pregnenolone does not interfere with the effects of cannabinoids on synaptic transmission in the cerebellum and the nucleus accumbens. <i>Pharmacological Research</i> , 2017, 123, 51-61.	7.1	7
69	Impact of Novel Psychoactive Substances on Clinical and Forensic Toxicology and Global Public Health. <i>Clinical Chemistry</i> , 2017, 63, 1564-1569.	3.2	31
70	Reply to Restolho et al. – Contactless decontamination of hair samples: cannabinoids™. <i>Drug Testing and Analysis</i> , 2017, 9, 289-290.	2.6	1
71	Phase I metabolism of the highly potent synthetic cannabinoid MDMB-CHMICA and detection in human urine samples. <i>Drug Testing and Analysis</i> , 2017, 9, 744-753.	2.6	54
72	Evaluation of CEDIA and DRI Drugs of Abuse Immunoassays for Urine Screening on a Thermo Indiko Plus Analyzer. <i>Journal of Clinical Laboratory Analysis</i> , 2017, 31, .	2.1	11

#	ARTICLE	IF	CITATIONS
73	Metabolites of synthetic cannabinoids in hair – proof of consumption or false friends for interpretation?. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 3445-3452.	3.7	45
74	Hair analysis for Δ^9 -tetrahydrocannabinolic acid A (THCA) and Δ^9 -tetrahydrocannabinol (THC) after handling cannabis plant material. <i>Drug Testing and Analysis</i> , 2016, 8, 128-132.	2.6	21
75	Characterization and <i>in vitro</i> phase I microsomal metabolism of designer benzodiazepines – an update comprising adinazolam, cloniprazepam, fonazepam, Δ^9 -hydroxyphenazepam, metizolam and nitrazolam. <i>Journal of Mass Spectrometry</i> , 2016, 51, 1080-1089.	1.6	38
76	Investigations of the genotoxic properties of two synthetic cathinones (3-MMC, 4-MEC) which are used as psychoactive drugs. <i>Toxicology Research</i> , 2016, 5, 1410-1420.	2.1	6
77	Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites with a Newly Developed Bioassay. <i>Analytical Chemistry</i> , 2016, 88, 11476-11485.	6.5	193
78	Genotoxic properties of XLR-11, a widely consumed synthetic cannabinoid, and of the benzoyl indole RCS-4. <i>Archives of Toxicology</i> , 2016, 90, 3111-3123.	4.2	15
79	Separation and structural characterization of the new synthetic cannabinoid JWH-018 cyclohexyl methyl derivative Δ^9 -NE-CHMIMO using flash chromatography, GC-MS, IR and NMR spectroscopy. <i>Forensic Science International</i> , 2016, 266, e93-e98.	2.2	22
80	Adverse effects after the use of JWH-210 – a case series from the EU Spice II plus project. <i>Drug Testing and Analysis</i> , 2016, 8, 1030-1038.	2.6	47
81	Determination of medicinal and illicit drugs in post mortem dental hard tissues and comparison with analytical results for body fluids and hair samples. <i>Forensic Science International</i> , 2016, 265, 166-171.	2.2	25
82	Reply to “Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICA”. <i>Journal of Analytical Toxicology</i> , 2016, 40, 240-242.	2.8	30
83	Impact of a synthetic cannabinoid (CP-47,497-C8) on protein expression in human cells: evidence for induction of inflammation and DNA damage. <i>Archives of Toxicology</i> , 2016, 90, 1369-1382.	4.2	20
84	Detection of the ethanol consumption markers ethyl glucuronide and ethyl sulfate in urine samples from inmates of two German prisons. <i>International Journal of Legal Medicine</i> , 2016, 130, 387-391.	2.2	7
85	Neurobiological Aspects of Mindfulness in Pain Autoregulation: Unexpected Results from a Randomized-Controlled Trial and Possible Implications for Meditation Research. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 674.	2.0	20
86	Pharmakologie und Toxikologie synthetischer Cannabinoidrezeptor-Agonisten. , 2016, , 1-27.		0
87	Designer benzodiazepines: A new challenge. <i>World Psychiatry</i> , 2015, 14, 248-248.	10.4	81
88	Finding cannabinoids in hair does not prove cannabis consumption. <i>Scientific Reports</i> , 2015, 5, 14906.	3.3	51
89	Genotoxic properties of representatives of alkylindazoles and aminoalkyl-indoles which are consumed as synthetic cannabinoids. <i>Food and Chemical Toxicology</i> , 2015, 80, 130-136.	3.6	49
90	Two thiazolylindoles and a benzimidazole: Novel compounds on the designer drug market with potential cannabinoid receptor activity. <i>Forensic Science International</i> , 2015, 249, 133-147.	2.2	10

#	ARTICLE	IF	CITATIONS
91	Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MSn, and LC-HR-MS/MS. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 6697-6719.	3.7	66
92	Characterization of the four designer benzodiazepines clonazepam, deschloroetizolam, flubromazepam, and meclonazepam, and identification of their in vitro metabolites. <i>Forensic Toxicology</i> , 2015, 33, 388-395.	2.4	58
93	Hair analysis of synthetic cannabinoids: does the handling of herbal mixtures affect the analyst's hair concentration?. <i>Forensic Toxicology</i> , 2015, 33, 37-44.	2.4	15
94	Hair analysis for JWH-018, JWH-122, and JWH-210 after passive in vivo exposure to synthetic cannabinoid smoke. <i>Forensic Toxicology</i> , 2015, 33, 69-76.	2.4	14
95	Cannabinoid findings in children hair – what do they really tell us? An assessment in the light of three different analytical methods with focus on interpretation of Δ^9 -tetrahydrocannabinolic acid A concentrations. <i>Drug Testing and Analysis</i> , 2015, 7, 349-357.	2.6	31
96	Differences between the measured blood ethanol concentration and the estimated concentration by Widmark's equation in elderly persons. <i>Forensic Science International</i> , 2015, 247, 23-27.	2.2	11
97	Inhomogeneities in herbal mixtures: a serious risk for consumers. <i>Forensic Toxicology</i> , 2015, 33, 54-60.	2.4	36
98	Argon Mediates Anti-Apoptotic Signaling and Neuroprotection via Inhibition of Toll-Like Receptor 2 and 4. <i>PLoS ONE</i> , 2015, 10, e0143887.	2.5	32
99	Neuroprotection by Argon Ventilation after Perinatal Asphyxia: A Safety Study in Newborn Piglets. <i>PLoS ONE</i> , 2014, 9, e113575.	2.5	24
100	Response to –Absorption deficit and overshooting of the blood alcohol concentration–. <i>Medicine, Science and the Law</i> , 2014, 54, 235-235.	1.0	0
101	Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. <i>Drug Testing and Analysis</i> , 2014, 6, 757-763.	2.6	75
102	A comprehensive library-based, automated screening procedure for 46 synthetic cannabinoids in serum employing liquid chromatography–quadrupole ion trap mass spectrometry with high-temperature electrospray ionization. <i>Journal of Mass Spectrometry</i> , 2014, 49, 117-127.	1.6	47
103	Investigation of the in vitro toxicological properties of the synthetic cannabimimetic drug CP-47,497-C8. <i>Toxicology and Applied Pharmacology</i> , 2014, 277, 164-171.	2.8	50
104	–Psychotropics caught in a trap– – Adopting a screening approach to specific needs. <i>Forensic Science International</i> , 2014, 243, 84-89.	2.2	26
105	Determination of Δ^9 -tetrahydrocannabinolic acid A (Δ^9 -THCA-A) in whole blood and plasma by LC–MS/MS and application in authentic samples from drivers suspected of driving under the influence of cannabis. <i>Forensic Science International</i> , 2014, 243, 130-136.	2.2	38
106	Pharmacokinetics of GHB and detection window in serum and urine after single uptake of a low dose of GBL – an experiment with two volunteers. <i>Drug Testing and Analysis</i> , 2014, 6, 363-366.	2.6	39
107	Analysis of synthetic cannabinoids in abstinence control: long drug detection windows in serum and implications for practitioners. <i>Drug Testing and Analysis</i> , 2014, 6, 135-136.	2.6	20
108	Driving under the influence of synthetic cannabinoids (–Spice–): a case series. <i>International Journal of Legal Medicine</i> , 2014, 128, 59-64.	2.2	101

#	ARTICLE	IF	CITATIONS
109	Hair analysis for THCA, THC and CBN after passive <i>in vivo</i> exposure to marijuana smoke. Drug Testing and Analysis, 2014, 6, 119-125.	2.6	49
110	Synthetic Cannabinoid Receptor Agonists. , 2013, , 317-343.		12
111	Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM2201 regarding its chemistry and metabolism. Journal of Mass Spectrometry, 2013, 48, 885-894.	1.6	94
112	A fast and inexpensive procedure for the isolation of synthetic cannabinoids from "Spice"™ products using a flash chromatography system. Analytical and Bioanalytical Chemistry, 2013, 405, 3929-3935.	3.7	15
113	Development and validation of an LC-MS/MS method for quantification of δ^9 -tetrahydrocannabinolic acid A (THCA-A), THC, CBN and CBD in hair. Journal of Mass Spectrometry, 2013, 48, 227-233.	1.6	43
114	Analysis of 30 synthetic cannabinoids in oral fluid using liquid chromatography-electrospray ionization tandem mass spectrometry. Drug Testing and Analysis, 2013, 5, 657-669.	2.6	67
115	LC/ESI-MS/MS method for quantification of 28 synthetic cannabinoids in neat oral fluid and its application to preliminary studies on their detection windows. Analytical and Bioanalytical Chemistry, 2013, 405, 4691-4706.	3.7	60
116	Ethanol Concentration in Breastmilk After the Consumption of Non-alcoholic Beer. Breastfeeding Medicine, 2013, 8, 291-293.	1.7	10
117	Acute intoxication by synthetic cannabinoids " Four case reports. Drug Testing and Analysis, 2013, 5, 790-794.	2.6	73
118	Toxicological profiles of selected synthetic cannabinoids showing high binding affinities to the cannabinoid receptor subtype CB1. Archives of Toxicology, 2013, 87, 1287-1297.	4.2	57
119	Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine. Forensic Toxicology, 2013, 31, 263-271.	2.4	46
120	Stability of 11 prevalent synthetic cannabinoids in authentic neat oral fluid samples: glass versus polypropylene containers at different temperatures. Drug Testing and Analysis, 2013, 5, 602-606.	2.6	21
121	Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction, 2013, 108, 534-544.	3.3	397
122	Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics. Journal of Mass Spectrometry, 2013, 48, 1150-1159.	1.6	81
123	A case of a distinct difference between the measured blood ethanol concentration and the concentration estimated by Widmark's equation. Medicine, Science and the Law, 2013, 53, 96-99.	1.0	7
124	Desalkylflurazepam found in patients' samples after high-dose midazolam treatment. Drug Testing and Analysis, 2013, 5, 745-747.	2.6	7
125	Regioselective synthesis of isotopically labeled δ^9 -tetrahydrocannabinolic acid A (THCA-A-D3) by reaction of δ^9 -tetrahydrocannabinol-D3 with magnesium methyl carbonate. Forensic Science International, 2012, 222, 368-72.	2.2	1
126	Separation and structural characterization of the synthetic cannabinoids JWH-412 and 1-[(5-fluoropentyl)-1H-indol-3-yl]-(4-methylnaphthalen-1-yl)methanone using GC-MS, NMR analysis and a flash chromatography system. Forensic Science International, 2012, 220, e17-e22.	2.2	59

#	ARTICLE	IF	CITATIONS
127	Determination of 22 synthetic cannabinoids in human hair by liquid chromatography–tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 903, 95-101.	2.3	104
128	Cocktail Approach for In Vivo Phenotyping of 5 Major CYP450 Isoenzymes: Development of an Effective Sampling, Extraction, and Analytical Procedure and Pilot Study With Comparative Genotyping. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1200-1214.	2.0	25
129	Identification of the cannabimimetic AM-1220 and its azepane isomer (N-methylazepan-3-yl)-3-(1-naphthoyl)indole in a research chemical and several herbal mixtures. <i>Forensic Toxicology</i> , 2012, 30, 126-134.	2.4	46
130	Analysis of 30 synthetic cannabinoids in serum by liquid chromatography–electrospray ionization tandem mass spectrometry after liquid–liquid extraction. <i>Journal of Mass Spectrometry</i> , 2012, 47, 825-835.	1.6	121
131	LC–MS/MS analysis of Δ^9 -tetrahydrocannabinolic acid A in serum after protein precipitation using an in-house synthesized deuterated internal standard. <i>Journal of Mass Spectrometry</i> , 2012, 47, 778-785.	1.6	11
132	Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in “herbal mixtures” using LC–MS/MS techniques. <i>Journal of Mass Spectrometry</i> , 2012, 47, 54-65.	1.6	133
133	Identification and structural characterization of the synthetic cannabinoid 3-(1-(adamantoyl)-1-pentylindole as an additive in “herbal incense”. <i>Journal of Mass Spectrometry</i> , 2012, 47, 195-200.	1.6	42
134	Rapid isolation procedure for Δ^9 -tetrahydrocannabinolic acid A (THCA) from <i>Cannabis sativa</i> using two flash chromatography systems. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 3059-3064.	2.3	29
135	Sensitive quantification of clozapine and its main metabolites norclozapine and clozapine-N-oxide in serum and urine using LC-MS/MS after simple liquid–liquid extraction work-up. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 400, 737-746.	3.7	29
136	Ethyl sulphate and ethyl glucuronide in vitreous humor as postmortem evidence marker for ethanol consumption prior to death. <i>Forensic Science International</i> , 2011, 210, 63-68.	2.2	44
137	Intrahepatic Cholestasis Following Abuse of Powdered Kratom (<i>Mitragyna speciosa</i>). <i>Journal of Medical Toxicology</i> , 2011, 7, 227-231.	1.5	116
138	Development and validation of a liquid chromatography–tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. <i>Journal of Mass Spectrometry</i> , 2011, 46, 163-171.	1.6	131
139	Complex suicide by ethanol intoxication and inhalation of fire fumes in an old lady: Interdisciplinary elucidation including post-mortem analysis of congener alcohols. <i>Forensic Science International</i> , 2011, 209, e11-e15.	2.2	21
140	Cannabinoid Receptor 2 Signaling Does Not Modulate Atherogenesis in Mice. <i>PLoS ONE</i> , 2011, 6, e19405.	2.5	21
141	Identification of 48 homologues of phosphatidylethanol in blood by LC-ESI-MS/MS. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 396, 2415-2423.	3.7	119
142	Urine tested positive for ethyl glucuronide and ethyl sulfate after the consumption of yeast and sugar. <i>Forensic Science International</i> , 2010, 202, e45-e47.	2.2	29
143	A survey of warning colours of pesticides. <i>Forensic Science, Medicine, and Pathology</i> , 2010, 6, 307-313.	1.4	2
144	Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. <i>Journal of Mass Spectrometry</i> , 2010, 45, 1186-1194.	1.6	268

#	ARTICLE	IF	CITATIONS
145	Computer assisted modeling of ethyl sulfate pharmacokinetics. Forensic Science International, 2010, 194, 34-38.	2.2	7
146	Hair analysis for δ^9 -tetrahydrocannabinolic acid A—New insights into the mechanism of drug incorporation of cannabinoids into hair. Forensic Science International, 2010, 196, 10-13.	2.2	60
147	Urine tested positive for ethyl glucuronide and ethyl sulphate after the consumption of a non-alcoholic beer. Forensic Science International, 2010, 202, 82-85.	2.2	42
148	Continuous microfluidic DNA extraction using phase-transfer magnetophoresis. Lab on A Chip, 2010, 10, 3284.	6.0	86
149	Volatile congeners in alcoholic beverages: analysis and forensic significance. Romanian Journal of Legal Medicine, 2010, 18, 265-270.	0.3	9
150	Spice™ and other herbal blends: harmless incense or cannabinoid designer drugs?. Journal of Mass Spectrometry, 2009, 44, 832-837.	1.6	588
151	Selective detection of phosphatidylethanol homologues in blood as biomarkers for alcohol consumption by LC-ESI-MS/MS. Journal of Mass Spectrometry, 2009, 44, 1293-1299.	1.6	61
152	Studies on the metabolism of the δ^9 -tetrahydrocannabinol precursor δ^9 -tetrahydrocannabinolic acid A (δ^9 -THCA) in rat using LC-MS/MS, LC-QTOF MS and GC-MS techniques. Journal of Mass Spectrometry, 2009, 44, 1423-1433.	2.0	48
153	Drug dosing error with drops—severe clinical course of codeine intoxication in twins. European Journal of Pediatrics, 2009, 168, 819-824.	2.7	39
154	Suicidal poisoning with mercaptodimethur—morphological findings and toxicological analysis. International Journal of Legal Medicine, 2009, 123, 327-331.	2.2	10
155	Fatal and severe codeine intoxication in 3-year-old twins—interpretation of drug and metabolite concentrations. International Journal of Legal Medicine, 2009, 123, 387-394.	2.2	36
156	Urine tested positive for ethyl glucuronide after trace amounts of ethanol. Addiction, 2009, 104, 2007-2012.	3.3	54
157	Identification of sinicuichi alkaloids in human serum after intoxication caused by oral intake of a Heimia salicifolia extract. Forensic Science International, 2008, 179, e57-e61.	2.2	8
158	Kinetics in serum and urinary excretion of ethyl sulfate and ethyl glucuronide after medium dose ethanol intake. International Journal of Legal Medicine, 2008, 122, 123-128.	2.2	137
159	Measurement of direct ethanol metabolites in a case of a former driving under the influence (DUI) of alcohol offender, now claiming abstinence. International Journal of Legal Medicine, 2008, 122, 235-239.	2.2	37
160	Assessment of Alcohol Use Among Methadone Maintenance Patients by Direct Ethanol Metabolites and Self-Reports. Alcoholism: Clinical and Experimental Research, 2008, 32, 1552-1557.	2.4	42
161	Sevoflurane-Mediated Activation of p38-Mitogen-Activated Stresskinase is Independent of Apoptosis in Jurkat T-Cells. Anesthesia and Analgesia, 2008, 106, 1150-1160.	2.2	22
162	Toxicological analysis after asphyxial suicide with helium and a plastic bag. Forensic Science International, 2007, 170, 139-141.	2.2	51

#	ARTICLE	IF	CITATIONS
163	Functional residual capacity measurement by heptafluoropropane in ventilated newborn lungs: In vitro and in vivo validation. <i>Critical Care Medicine</i> , 2006, 34, 1789-1795.	0.9	18
164	Determination of 1,1,1,2,3,3,3-Heptafluoropropane (HFP) in Blood by Headspace Gas Chromatography-Mass Spectrometry. <i>Journal of Analytical Toxicology</i> , 2005, 29, 574-576.	2.8	7
165	CONCENTRATION OF FATTY ACID ETHYL ESTERS IN HAIR OF ALCOHOLICS: COMPARISON TO OTHER BIOLOGICAL STATE MARKERS AND SELF REPORTED-ETHANOL INTAKE. <i>Alcohol and Alcoholism</i> , 2004, 39, 33-38.	1.6	93
166	Wipe-test and patch-test for alcohol misuse based on the concentration ratio of fatty acid ethyl esters and squalene CFAEE/CSQ in skin surface lipids. <i>Forensic Science International</i> , 2004, 143, 77-86.	2.2	31
167	Squalene in hair – a natural reference substance for the improved interpretation of fatty acid ethyl ester concentrations with respect to alcohol misuse. <i>Forensic Science International</i> , 2004, 145, 149-159.	2.2	24
168	Comparison of ethyl glucuronide and fatty acid ethyl ester concentrations in hair of alcoholics, social drinkers and teetotalers. <i>Forensic Science International</i> , 2004, 145, 167-173.	2.2	174
169	Analytical investigations in a death case by suffocation in an argon atmosphere. <i>Forensic Science International</i> , 2004, 143, 169-175.	2.2	22
170	Effect of hair care and hair cosmetics on the concentrations of fatty acid ethyl esters in hair as markers of chronically elevated alcohol consumption. <i>Forensic Science International</i> , 2003, 131, 90-97.	2.2	90
171	FATTY ACID ETHYL ESTERS IN SCALP, PUBIC, AXILLARY, BEARD AND BODY HAIR AS MARKERS FOR ALCOHOL MISUSE. <i>Alcohol and Alcoholism</i> , 2003, 38, 163-167.	1.6	49
172	Analysis of fatty acid ethyl esters in hair as possible markers of chronically elevated alcohol consumption by headspace solid-phase microextraction (HS-SPME) and gas chromatography-mass spectrometry (GC-MS). <i>Forensic Science International</i> , 2001, 121, 76-88.	2.2	147
173	New psychoactive substances – Designer benzodiazepines. <i>Wiley Interdisciplinary Reviews Forensic Science</i> , 0, , .	2.1	3
174	A case of fatal multidrug intoxication involving flualprazolam: distribution in body fluids and solid tissues. <i>Forensic Toxicology</i> , 0, , 1.	2.4	2
175	Assessment of Benzodiazepine (BZD) Use Among Nursing Home Residents by Liquid Chromatography-Tandem Mass Spectrometry, Nursing Questionnaires, and Examining Additional Mental Health Problems of BZD Users. <i>International Journal of Mental Health and Addiction</i> , 0, , 1.	7.4	0